DBVT DBV Technologies S.A. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$16.59

Period return

-0.39 (-2.30%)

Volume

273.5K

2026-06-05O $17.06 H $17.26 L $16.41 C $16.59MA5 $17.78MA20 $18.77MA60 $19.81MA120 $20.34

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 04.LowBUYlast month
Guggenheim: Buy
US analyst rating / recommendation change.
2026. 05. 01.LowBUYlast month
Citizens: Market Outperform
US analyst rating / recommendation change.
2026. 03. 27.LowBUY2 months ago
Citizens: Market Outperform
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $40.7 · 6 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Sector: Healthcare
Industry: Biotechnology
HQ: Châtillon, France
Fiscal year end: —
Employees: 161
IPO date: —

View details →

2026. 03. 27.LowBUY2 months ago

Guggenheim: Buy